Theriva Biologics, Inc. (TOVX)
USD 1.17
(-1.68%)
USD 1.17
(-1.68%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.51 Million USD | 18.6% |
| 2022 | 17.29 Million USD | 248.94% |
| 2021 | 4.95 Million USD | 57.27% |
| 2020 | 3.15 Million USD | -45.16% |
| 2019 | 5.74 Million USD | 55.94% |
| 2018 | 3.68 Million USD | -83.43% |
| 2017 | 22.24 Million USD | 9.87% |
| 2016 | 20.24 Million USD | 27.82% |
| 2015 | 15.84 Million USD | 65.23% |
| 2014 | 9.58 Million USD | 833.59% |
| 2013 | 1.02 Million USD | 160.0% |
| 2012 | 395 Thousand USD | -5.28% |
| 2011 | 417 Thousand USD | -21.69% |
| 2010 | 532.48 Thousand USD | 0.2% |
| 2009 | 531.43 Thousand USD | -14.38% |
| 2008 | 620.71 Thousand USD | -63.22% |
| 2007 | 1.68 Million USD | 131.48% |
| 2006 | 729.01 Thousand USD | -65.99% |
| 2005 | 2.14 Million USD | 0.0% |
| 2002 | 16.9 Million USD | 51.68% |
| 2001 | 11.14 Million USD | 90.0% |
| 2000 | 5.86 Million USD | 33.96% |
| 1999 | 4.37 Million USD | 98.98% |
| 1998 | 2.2 Million USD | -24.14% |
| 1997 | 2.9 Million USD | 163.64% |
| 1996 | 1.1 Million USD | 175.0% |
| 1995 | 400 Thousand USD | -55.56% |
| 1994 | 900 Thousand USD | 350.0% |
| 1993 | 200 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 14.74 Million USD | 0.94% |
| 2024 Q1 | 14.6 Million USD | -28.79% |
| 2023 Q4 | 20.51 Million USD | 16.15% |
| 2023 Q2 | 17.69 Million USD | 2.29% |
| 2023 Q3 | 17.66 Million USD | -0.2% |
| 2023 FY | 20.51 Million USD | 18.6% |
| 2023 Q1 | 17.3 Million USD | 0.02% |
| 2022 FY | 17.29 Million USD | 248.94% |
| 2022 Q1 | 20.97 Million USD | 323.08% |
| 2022 Q2 | 20.65 Million USD | -1.5% |
| 2022 Q3 | 20.54 Million USD | -0.54% |
| 2022 Q4 | 17.29 Million USD | -15.81% |
| 2021 Q4 | 4.95 Million USD | 8.68% |
| 2021 Q1 | 2.23 Million USD | -29.25% |
| 2021 Q2 | 3.52 Million USD | 58.03% |
| 2021 FY | 4.95 Million USD | 57.27% |
| 2021 Q3 | 4.56 Million USD | 29.43% |
| 2020 Q1 | 3.28 Million USD | -42.92% |
| 2020 Q4 | 3.15 Million USD | -3.64% |
| 2020 Q3 | 3.27 Million USD | -13.07% |
| 2020 Q2 | 3.76 Million USD | 14.69% |
| 2020 FY | 3.15 Million USD | -45.16% |
| 2019 Q3 | 6.17 Million USD | 39.89% |
| 2019 FY | 5.74 Million USD | 55.94% |
| 2019 Q4 | 5.74 Million USD | -6.87% |
| 2019 Q2 | 4.41 Million USD | 21.74% |
| 2019 Q1 | 3.62 Million USD | -1.68% |
| 2018 FY | 3.68 Million USD | -83.43% |
| 2018 Q4 | 3.68 Million USD | -13.13% |
| 2018 Q3 | 4.24 Million USD | -9.18% |
| 2018 Q2 | 4.67 Million USD | -14.49% |
| 2018 Q1 | 5.46 Million USD | -75.44% |
| 2017 Q1 | 16.95 Million USD | -16.25% |
| 2017 FY | 22.24 Million USD | 9.87% |
| 2017 Q2 | 12.77 Million USD | -24.65% |
| 2017 Q4 | 22.24 Million USD | -25.7% |
| 2017 Q3 | 29.94 Million USD | 134.33% |
| 2016 Q4 | 20.24 Million USD | 42.36% |
| 2016 Q2 | 15.4 Million USD | -13.32% |
| 2016 FY | 20.24 Million USD | 27.82% |
| 2016 Q1 | 17.76 Million USD | 12.14% |
| 2016 Q3 | 14.22 Million USD | -7.64% |
| 2015 Q4 | 15.84 Million USD | -9.47% |
| 2015 Q2 | 25.49 Million USD | 66.21% |
| 2015 Q1 | 15.34 Million USD | 60.0% |
| 2015 FY | 15.84 Million USD | 65.23% |
| 2015 Q3 | 17.49 Million USD | -31.37% |
| 2014 Q4 | 9.58 Million USD | 874.39% |
| 2014 Q3 | 984 Thousand USD | -20.13% |
| 2014 Q2 | 1.23 Million USD | 59.38% |
| 2014 Q1 | 773 Thousand USD | -24.73% |
| 2014 FY | 9.58 Million USD | 833.59% |
| 2013 FY | 1.02 Million USD | 160.0% |
| 2013 Q4 | 1.02 Million USD | 75.86% |
| 2013 Q3 | 584 Thousand USD | 155.02% |
| 2013 Q2 | 229 Thousand USD | 16.84% |
| 2013 Q1 | 196 Thousand USD | -50.38% |
| 2012 Q1 | 443 Thousand USD | 6.24% |
| 2012 FY | 395 Thousand USD | -5.28% |
| 2012 Q4 | 395 Thousand USD | -5.28% |
| 2012 Q3 | 417 Thousand USD | 5.57% |
| 2012 Q2 | 395 Thousand USD | -10.84% |
| 2011 Q1 | 1.2 Million USD | 125.38% |
| 2011 Q3 | 236.36 Thousand USD | -40.94% |
| 2011 FY | 417 Thousand USD | -21.69% |
| 2011 Q2 | 400.21 Thousand USD | -66.65% |
| 2011 Q4 | 417 Thousand USD | 76.42% |
| 2010 Q3 | 441.08 Thousand USD | -35.73% |
| 2010 Q4 | 532.48 Thousand USD | 20.72% |
| 2010 FY | 532.48 Thousand USD | 0.2% |
| 2010 Q1 | 501.15 Thousand USD | -5.7% |
| 2010 Q2 | 686.35 Thousand USD | 36.95% |
| 2009 Q3 | 449.07 Thousand USD | -21.82% |
| 2009 Q2 | 574.4 Thousand USD | -26.77% |
| 2009 Q1 | 784.43 Thousand USD | 26.38% |
| 2009 FY | 531.43 Thousand USD | -14.38% |
| 2009 Q4 | 531.43 Thousand USD | 18.34% |
| 2008 Q2 | 816.19 Thousand USD | -38.05% |
| 2008 Q4 | 620.71 Thousand USD | -8.32% |
| 2008 FY | 620.71 Thousand USD | -63.22% |
| 2008 Q1 | 1.31 Million USD | -21.93% |
| 2008 Q3 | 677.03 Thousand USD | -17.05% |
| 2007 FY | 1.68 Million USD | 131.48% |
| 2007 Q3 | 1.75 Million USD | 7.84% |
| 2007 Q4 | 1.68 Million USD | -4.1% |
| 2007 Q2 | 1.63 Million USD | 42.89% |
| 2007 Q1 | 1.14 Million USD | 56.64% |
| 2006 Q4 | 729.01 Thousand USD | 24063.71% |
| 2006 Q1 | 9350.00 USD | 0.0% |
| 2006 Q2 | - USD | -100.0% |
| 2006 Q3 | 3017.00 USD | 0.0% |
| 2006 FY | 729.01 Thousand USD | -65.99% |
| 2005 FY | 2.14 Million USD | 0.0% |
| 2003 Q1 | 17.48 Million USD | 3.47% |
| 2002 Q3 | 16.18 Million USD | 5.09% |
| 2002 Q2 | 15.39 Million USD | 15.72% |
| 2002 FY | 16.9 Million USD | 51.68% |
| 2002 Q1 | 13.3 Million USD | 19.43% |
| 2002 Q4 | 16.9 Million USD | 4.44% |
| 2001 Q4 | 11.14 Million USD | 27.32% |
| 2001 Q3 | 8.75 Million USD | 38.32% |
| 2001 Q1 | 5.52 Million USD | -5.79% |
| 2001 FY | 11.14 Million USD | 90.0% |
| 2001 Q2 | 6.32 Million USD | 14.52% |
| 2000 Q4 | 5.86 Million USD | 40.9% |
| 2000 FY | 5.86 Million USD | 33.96% |
| 2000 Q3 | 4.16 Million USD | 0.52% |
| 2000 Q1 | 4.14 Million USD | -5.23% |
| 2000 Q2 | 4.14 Million USD | -0.2% |
| 1999 FY | 4.37 Million USD | 98.98% |
| 1999 Q1 | 2.8 Million USD | 27.27% |
| 1999 Q2 | 3.5 Million USD | 25.0% |
| 1999 Q3 | 1.6 Million USD | -54.29% |
| 1999 Q4 | 4.37 Million USD | 173.6% |
| 1998 FY | 2.2 Million USD | -24.14% |
| 1998 Q1 | 3.9 Million USD | 34.48% |
| 1998 Q4 | 2.2 Million USD | 46.67% |
| 1998 Q3 | 1.5 Million USD | 25.0% |
| 1998 Q2 | 1.2 Million USD | -69.23% |
| 1997 FY | 2.9 Million USD | 163.64% |
| 1997 Q2 | 900 Thousand USD | -40.0% |
| 1997 Q3 | 2.9 Million USD | 222.22% |
| 1997 Q4 | 2.9 Million USD | 0.0% |
| 1997 Q1 | 1.5 Million USD | 36.36% |
| 1996 FY | 1.1 Million USD | 175.0% |
| 1996 Q4 | 1.1 Million USD | 57.14% |
| 1996 Q3 | 700 Thousand USD | -12.5% |
| 1996 Q2 | 800 Thousand USD | 100.0% |
| 1996 Q1 | 400 Thousand USD | 0.0% |
| 1995 FY | 400 Thousand USD | -55.56% |
| 1995 Q3 | 400 Thousand USD | 0.0% |
| 1995 Q4 | 400 Thousand USD | 0.0% |
| 1994 Q1 | 200 Thousand USD | 0.0% |
| 1994 Q4 | 900 Thousand USD | 0.0% |
| 1994 FY | 900 Thousand USD | 350.0% |
| 1993 Q1 | 900 Thousand USD | 0.0% |
| 1993 Q4 | 200 Thousand USD | 0.0% |
| 1993 Q2 | 200 Thousand USD | -77.78% |
| 1993 Q3 | - USD | -100.0% |
| 1993 FY | 200 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ADC Therapeutics SA | 503.03 Million USD | 95.922% |
| Alto Neuroscience, Inc. | 158.3 Million USD | 87.041% |
| Annovis Bio, Inc. | 17.95 Million USD | -14.226% |
| Biohaven Pharmaceutical Holding Company Ltd. | 85.23 Million USD | 75.933% |
| Ginkgo Bioworks Holdings, Inc. | 568.19 Million USD | 96.39% |
| Nuvation Bio Inc. | 16.36 Million USD | -25.376% |
| Nuvation Bio Inc. | 16.36 Million USD | -25.376% |
| Arcus Biosciences, Inc. | 633 Million USD | 96.759% |
| Zymeworks Inc. | 116.07 Million USD | 82.327% |